The Delta-plus variant, Indian SARS-CoV-2 Genomic Consortia (INSACOG) said, has increased transmissibility, stronger binding to receptors of lung cells and has the potential to reduce response to monoclonal antibody treatment.
The ministry has issued an advisory to these states to take more focused and effective public health response measures. The chief secretaries of these states have been advised to take up immediate containment measures in the districts and clusters.
The variant is present in nine other countries — the US, the UK, Portugal, Switzerland, Japan, Poland, China, Nepal, and Russia.
In India, this variant has been found in genome sequenced samples from Ratnagiri and Jalgaon districts of Maharashtra, Palakkad, and Pathanamthitta districts of Kerala; and Bhopal and Shivpuri districts of Madhya Pradesh.
“Cases look fairly small but we do not want it assuming a significant proportion,” Rajesh Bhushan, health secretary, said.
Twenty-eight labs in the Indian SARS-CoV-2 Genomic Consortia are sequencing samples to monitor the variants. So far INSACOG has sequenced 45,000 samples.
Delta and Delta Plus variants of Sars-CoV-2 are causing concern among doctors and researchers as the world tries to map the spread, virulence and potential risks of these mutations.
To read the full story, Subscribe Now at just Rs 249 a month
Already a subscriber? Log in
Subscribe To BS Premium
₹249
Renews automatically
₹1699₹1999
Opt for auto renewal and save Rs. 300 Renews automatically
₹1999
What you get on BS Premium?
- Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
- Pick your 5 favourite companies, get a daily email with all news updates on them.
- Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
- Preferential invites to Business Standard events.
- Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Need More Information - write to us at assist@bsmail.in